Do Clinical Features and Survival of Single Hormone Receptor Positive Breast Cancers Differ from Double Hormone Receptor Positive Breast Cancers?

Ng, Char-Hong; Pathy, Nirmala Bhoo; Taib, Nur Aishah; Ho, Gwo-Fuang; Mun, Kein-Seong; Rhodes, Anthony; Looi, Lai-Meng; Yip, Cheng-Har

추천

검색

자료유형: 학술저널

저자정보: Ng, Char-Hong (Department of Surgery, University Malaya Medical Centre) Pathy, Nirmala Bhoo (Julius Center University of Malaya, Faculty of Medicine, University of Malaya) Taib, Nur Aishah (Department of Surgery, University Malaya Medical Centre) Ho, Gwo-Fuang (Oncology and Radiotherapy Unit, University Malaya Medical Centre) Mun, Kein-Seong (Department of Pathology, University Malaya Medical Centre) Rhodes, Anthony (Department of Pathology, University Malaya Medical Centre) Looi, Lai-Meng (Department of Pathology, University Malaya Medical Centre) Yip, Cheng-Har (Department of Surgery, University Malaya Medical Centre)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제18호

발행연도: 2014.1

수록면: 7,959 - 7,964 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

The significance of the single hormone receptor positive phenotype of breast cancer is still poorly understood. The use of hormone therapy has been found to be less effective for this type, which has a survival outcome midway between double positive and double negative phenotypes. The aim of this study was to investigate differences in patient and tumor characteristics and survival between double-receptor positive (ER+PR+), double receptor negative (ER-PR-) and single receptor positive (ER+PR- and ER-PR+) breast cancer in an Asian setting. A total of 1,992 patients with newly diagnosed stage I to IV breast cancer between 2003 and 2008, and where information on ER and PR were available, were included in this study. The majority of patients had ER+PR+ tumors (n=903: 45.3%), followed by 741 (37.2%) ER-PR-, 247 (12.4%) ER+PR-, and 101 (5.1%) ER-PR+ tumors. Using multivariate analysis, ER+PR- tumors were 2.4 times more likely to be grade 3 compared to ER+PR+ tumors. ER+PR- and ER-PR+ tumors were 82% and 86% respectively less likely to be grade 3 compared with ER-PR- tumors. ER-PR+ tumours were associated with younger age. There were no survival differences between patients with ER+PR+ and ER-PR+ tumors. However, ER+PR- tumors have poorer survival compared with ER+PR+ tumours. ER-PR- tumours had the worst survival. Adjuvant hormonal therapy with tamoxifen was found to have identical survival advantage in patients with ER+PR+ and ER-PR+ tumors whereas impact was slightly lower in patients with ER+PR- tumors. In conclusion, we found ER+PR- tumors to be more aggressive and have poorer survival when compared to ER+PR+ tumors, while patients with ER-PR+ tumours were younger, but had a similar survival to their counterparts with ER+PR+ tumours.

#Breast cancer #hormonal receptors #ER-PR+ subtype #survival outcome

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요